Author(s): Aghaei S
Abstract Share this page
Abstract BACKGROUND: Alopecia areata (AA) is an autoimmune disease mediated by T lymphocytes. Many treatments have been used but their results remain disappointing. There is a need to propose new therapeutic alternatives. METHODS: During a period of 3 years, 26 patients with recalcitrant or severe AA (>40\% hair loss) were enrolled in an open-label uncontrolled clinical trial. According to the response to sulfasalazine, patients were grouped into 3 categories: no hair regrowth (< 10\% terminal hair), partial hair regrowth (10\%-90\% terminal hair), and complete hair regrowth (90\%-100\% terminal hair). Efficacy evaluation was performed with clinical examination. RESULTS: Twenty-two patients completed the treatment. Overall, 68.2\% (15 of 22 patients) responded to therapy: 27.3\% (6 of 22 patients) achieved complete hair regrowth, and 40.9\% had partial hair regrowth. Seven (31.8\%) patients had no hair regrowth. Of the 22 patients with complete and partial remission, 10 (45.5\%) suffered a partial or complete relapse. Side effects following treatment were seen in 7 (31.8\%) patients. CONCLUSION: Sulfasalazine could be considered as a therapeutic alternative in the treatment of AA, because of its safety profile, cosmetically acceptable efficacy, and good tolerability.
This article was published in Indian J Dermatol Venereol Leprol
and referenced in Hair Therapy & Transplantation